Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts Sells 7,179 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 7,179 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $7.32, for a total transaction of $52,550.28. Following the completion of the sale, the chief financial officer now owns 291,486 shares of the company’s stock, valued at $2,133,677.52. This trade represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Austin Aerts also recently made the following trade(s):

• On Tuesday, September 10th, Austin Aerts sold 5,056 shares of Sera Prognostics stock. The shares were sold at an average price of $7.57, for a total value of $38,273.92.

Sera Prognostics Trading Down 7.6 %

SERA opened at $6.44 on Friday. Sera Prognostics, Inc. has a 12-month low of $1.67 and a 12-month high of $12.35. The stock has a fifty day simple moving average of $7.38 and a two-hundred day simple moving average of $7.64.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same period in the prior year, the business posted ($0.23) earnings per share. Research analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

Hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. lifted its position in Sera Prognostics by 12.7% in the 2nd quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after acquiring an additional 2,891 shares in the last quarter. Quest Partners LLC lifted its holdings in shares of Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after purchasing an additional 5,415 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Sera Prognostics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock valued at $135,000 after buying an additional 9,722 shares during the last quarter. SG Americas Securities LLC bought a new stake in Sera Prognostics in the 3rd quarter worth about $78,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Sera Prognostics in the 2nd quarter worth about $68,000. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.